Cargando…

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer

BACKGROUND: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milbar, Niv, Kates, Max, Chappidi, Meera R., Pederzoli, Filippo, Yoshida, Takahiro, Sankin, Alexander, Pierorazio, Phillip M., Schoenberg, Mark P., Bivalacqua, Trinity J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676758/ https://www.ncbi.nlm.nih.gov/pubmed/29152553 http://dx.doi.org/10.3233/BLC-170126

Ejemplares similares

High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer
por: Kates, Max, et al.
Publicado: (2017)

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
por: McElree, Ian M., et al.
Publicado: (2023)

Do African American Patients Treated with Radical Cystectomy for Bladder Cancer have Worse Overall Survival? Accounting for Pathologic Staging and Patient Demographics Beyond Race Makes a Difference
por: Kaye, Deborah R., et al.
Publicado: (2016)

Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells
por: Yoshida, Takahiro, et al.
Publicado: (2018)

Docetaxel/gemcitabine: Various toxicities: 4 case reports
Publicado: (2021)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
por: Han, Mi Ah, et al.
Publicado: (2021)

Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture
por: Mi, Haoyang, et al.
Publicado: (2021)

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer
por: Douglass, Laura, et al.
Publicado: (2016)

Comparative study of sequential intravesical chemotherapy using gemcitabine and mitomycin C with mitomycin C alone for non-muscle invasive bladder carcinoma- a randomized trial
por: Jayant, Kumar, et al.
Publicado: (2015)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Co-Delivery of Cisplatin and Gemcitabine via Viscous Nanoemulsion for Potential Synergistic Intravesical Chemotherapy
por: Chen, Ting-Yu, et al.
Publicado: (2020)

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
por: Baras, Alexander S., et al.
Publicado: (2016)

Very high risk localized prostate cancer: definition and outcomes
por: Sundi, Debasish, et al.
Publicado: (2013)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
por: Joensuu, H., et al.
Publicado: (2010)

Organoid culture of bladder cancer cells
por: Yoshida, Takahiro, et al.
Publicado: (2018)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
por: Xu, Jie, et al.
Publicado: (2018)

Retrospective evaluation of the role of gemcitabine‐docetaxel in well‐differentiated and dedifferentiated liposarcoma
por: Thirasastr, Prapassorn, et al.
Publicado: (2022)

Regenerative Medicine for Erectile Dysfunction Following Radical Prostatectomy: Are we Ready?
por: Albersen, Maarten, et al.
Publicado: (2016)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
por: Lee, Ha-young, et al.
Publicado: (2012)

Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer
por: Li, Fenghu, et al.
Publicado: (2019)

Gemcitabine and Docetaxel Combination Chemotherapy Induced Dermatomyositis Associated with Hand-Foot Syndrome
por: Kawada, Mayuko, et al.
Publicado: (2021)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
por: Du, Zheng, et al.
Publicado: (2022)

Surgical excision of a large, verrucous, scrotal mass in a patient with HSV-2 and HIV-1 co-infection
por: Luderowski, Eva, et al.
Publicado: (2018)

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure
por: Shantharam, Govind, et al.
Publicado: (2021)

Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel
por: Son, Young-Min, et al.
Publicado: (2011)

Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder
por: Mohanty, N. K., et al.
Publicado: (2008)

Intravesically instilled gemcitabine-induced lung injury in a patient with invasive urothelial carcinoma: A case report
por: Zhou, Xiao-Ming, et al.
Publicado: (2020)

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
por: Palmerini, E., et al.
Publicado: (2016)

Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines
por: Lopez-Acevedo, Micael, et al.
Publicado: (2014)

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
por: Pender, Alexandra, et al.
Publicado: (2018)

Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
por: Choi, Yunjung, et al.
Publicado: (2018)

A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel
por: King, Nicholas, et al.
Publicado: (2019)

Curcumin enhances anti-cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells
por: Liu, Pan, et al.
Publicado: (2020)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o4ppl49jbkc0m28f2fikr6rrm6